MENU
Region
Worldwide Site
Gelesis SRL - Italy

A host of modern chronic diseases, such as obesity, NAFLD/NASH, IBD, and diabetes, originate in the GI pathway*.

*Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepititis (NASH) and Inflammatory Bowel Disease (IBD)

OBESITY

WEIGHT MANAGEMENT AND CHRONIC DISEASE

Half of all Americans report a desire to lose weight, but most attempts to maintain a healthy weight end in failure, and obesity rates continue to rise, increasing the burden on the health system.

2/3

of Americans have overweight or obesity

1.9B

adults globally have overweight and 600 million have obesity

>30

health conditions are linked to increased risk due to obesity

OBESITY IS A MEDICAL DISEASE THAT INCREASES THE RISK FOR OVER 30 HEALTH CONDITIONS

Given the potential for significant adverse events which limit their risk-benefit profile, current approaches to treat obesity, including surgery and prescription medications, are recommended to only a small percentage of individuals with obesity.

TYPE 2 DIABETES

A GROWING EPIDEMIC

Obesity is a major risk factor for developing prediabetes and diabetes. Approximately 85% of patients with type 2 diabetes are overweight or have obesity. In the United States, around 32 million adults have type 2 diabetes and an estimated 84 million have prediabetes (Source: CDC National Diabetes Statistics Report). Approximately 422 million have type 1 or type 2 diabetes worldwide (Source: 2016 WHO Global Report on Diabetes). A modest 5-7% weight loss has been shown to prevent conversion from prediabetes to diabetes in over 50% of patients. A safe, effective treatment that induces weight loss in people with prediabetes could potentially have a major impact on human health and may also result in tremendous savings for the healthcare system.

85%

of people with type 2 diabetes have overweight or obesity

>88M

Adults in the United States with prediabetes

Weight loss is first-line treatment recommendation for patients with diabetes or pre-diabetes

INFLAMMATORY
GI DISEASE

CONFRONTING NAFLD & NASH

Within the GI pathway, the health of the epithelial barrier and mucus layer may play an important role in the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), as well as diseases involving inflammation of the intestines, such as IBD. NAFLD is considered the most common liver disease in developed nations. NAFLD is defined as the accumulation of excessive fat in the liver in the absence of excessive drinking of alcohol and any secondary cause. An estimated 70-80% of people with obesity have NAFLD. Approximately 20% of patients with NAFLD develop NASH (approximately 5% of the worldwide population). NASH is the second leading indication for liver transplantation and 20-30% of people with NASH progress to cirrhosis/hepatocellular carcinoma.

70-80%

of people with obesity have nonalcoholic fatty liver disease

NAFLD is strongly associated with multiple serious conditions including obesity, metabolic/insulin resistance syndrome, and dyslipidemia

HEALTH RESOURCES

FOR MORE INFORMATION PLEASE VISIT:

SOURCES: American Diabetes Association, World Health Organization

LEARN MORE ABOUT OUR TECHNOLOGY

GELESIS PLATFORM